天津捷强动力装备股份有限公司 股票代码：300875 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 | | | 参与单位 名称及人 员姓名 | 华安基金、银河基金、德邦证券 | | | 时间 | 2022 年 2 月 23 日 | | | 地点 | 上海浦东香格里拉酒店 | | | 上市公司接 待人员姓名 | 董事会秘书刘群 | | ...

重要内容提示： 天津捷强动力装备股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 天津捷强动力装备股份有限公司 2022 年第三季度报告 证券代码：300875 证券简称：捷强装备 公告编号：2022-071 1 天津捷强动力装备股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 58,569,400.64 | -29.65% | 84,402,751.75 | -36.77% | | 归属于上市公司股东 | 9,402,452.86 | -60.47% | -10,705,078.35 | -132.02% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 3,095,040. ...

Financial Performance - The company's operating revenue for the reporting period was ¥25,833,351.11, a decrease of 48.56% compared to ¥50,221,328.32 in the same period last year [21]. - The net profit attributable to shareholders was -¥20,107,531.21, representing a decline of 308.49% from ¥9,644,367.31 in the previous year [21]. - The net cash flow from operating activities was -¥50,493,070.00, down 146.02% from ¥109,727,969.08 in the same period last year [21]. - Total assets at the end of the reporting period were ¥1,524,679,239.88, a decrease of 6.74% from ¥1,634,846,444.94 at the end of the previous year [21]. - The company's total operating revenue for the first half of 2022 was CNY 25.83 million, a decrease of CNY 24.39 million year-on-year [36]. - The net profit attributable to shareholders for the first half of 2022 was CNY -20.11 million, a decrease of 308.49% year-on-year [37]. - The net cash flow from operating activities was CNY -50.49 million, a decrease of 146.02% year-on-year [38]. - The company's total investment during the reporting period was ¥621,178,044.15, a decrease of 27.15% compared to ¥852,697,598.00 in the same period last year [70]. Research and Development - Research and development expenses totaled CNY 17.37 million, an increase of 20.58% year-on-year [37]. - The company's R&D investment reached 17.37 million yuan, a year-on-year increase of 20.58%, accounting for 67.22% of operating revenue [40]. - A total of 24 new R&D projects were initiated, focusing on key technologies in biosafety and custom equipment for nuclear radiation detection [40]. - The technical R&D team consists of 153 members, representing 42.27% of the total workforce, with a year-on-year growth of 17.69% [42]. - The company has developed multiple new products, enhancing its core competitiveness in the nuclear and biochemical safety equipment industry [43]. Market and Industry Trends - The nuclear and biochemical safety industry is experiencing increased demand due to diverse threats, driving the need for advanced safety equipment and solutions [32]. - The company focuses on the research, production, and sales of nuclear and biochemical safety equipment, catering to military, public safety, and healthcare sectors [29]. - The company is focusing on both military and civilian product expansion to create new profit growth points [39]. - The industry environment is favorable due to steady growth in national defense budgets and increased demand for nuclear and biochemical safety equipment [34]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans [3]. - The report includes a detailed analysis of potential risks and countermeasures the company may face in future operations [3]. - The company faces risks related to the lengthy and uncertain product development cycle for military products, which may adversely affect financial performance if new products do not receive military approval [107]. - Increased depreciation and amortization expenses from new fixed and intangible assets may pressure the company's profitability if market conditions worsen [108]. - The ongoing pandemic has created uncertainties, impacting production and operational activities, leading to potential delays in project timelines and revenue recognition [112]. Corporate Governance - The financial report ensures the accuracy and completeness of the data presented, with all board members present for the meeting [3]. - The company has not reported any discrepancies between net profit and net assets under international and domestic accounting standards [22][23]. - The company has not experienced any changes in its board of directors or senior management during the reporting period [119]. - The company has not engaged in any major litigation or arbitration matters during the reporting period, indicating a stable legal environment [140]. Shareholder Information - The company reported a cash distribution of RMB 23,038,788.90 during the reporting period, reflecting its commitment to providing reasonable returns to investors [127]. - The company distributed cash dividends of RMB 3.00 per 10 shares (including tax) and increased capital stock by 30% through a capital reserve conversion, resulting in a total share capital increase from 76,795,963 shares to 99,834,751 shares [127]. - The largest shareholder, Pan Feng, holds 25.41% of the shares, with an increase of 5,854,500 shares during the reporting period [172]. - The company has a total of 45,193,980 shares held by directors and senior management after an increase of 10,429,380 shares during the reporting period [176]. Environmental Responsibility - The company is committed to environmental protection and adheres to relevant laws and regulations [124]. - The company has conducted environmental impact assessments for its construction projects in compliance with regulations [124]. - The company implemented measures to reduce carbon emissions, with wastewater discharge meeting the Tier 3 standards of Tianjin's "Comprehensive Wastewater Discharge Standards" and noise emissions complying with the Class 3 standards of the "Industrial Enterprise Boundary Environmental Noise Emission Standards" [125]. Fundraising and Investment - The total amount raised from the initial public offering was RMB 1,019.47 million, with a net amount of RMB 927.00 million after deducting various issuance costs [86]. - The company has invested CNY 20 million in the military-civilian manufacturing center project, with a total investment of CNY 56 million to date [74]. - The company has a remaining balance of CNY 335 million in raised funds as of June 30, 2022 [82]. - The company has not reported any overdue or unrecovered amounts from entrusted wealth management [90]. Operational Efficiency - The company has strengthened production management and quality assurance, gaining high recognition from customers for its reliable products and services [128]. - The company has enhanced employee welfare and established stable labor relations, actively supporting union development and improving employee benefits [128]. - The company has established a service team composed of veterans and skilled technicians, receiving high praise for its technical and after-sales services [50].

Financial Performance - The company's revenue and net profit significantly decreased, with sales revenue from hydraulic power systems dropping to CNY 66.03 million, a year-on-year decline of 72.86%[6]. - The company's operating revenue for 2021 was ¥198,155,466.15, a decrease of 26.19% compared to ¥268,479,606.43 in 2020[28]. - The net profit attributable to shareholders for 2021 was ¥30,994,817.57, down 69.03% from ¥100,084,822.71 in 2020[28]. - The net profit after deducting non-recurring gains and losses was ¥11,554,919.20, a decline of 87.73% from ¥94,156,688.71 in 2020[28]. - The company reported a net profit of ¥4,287,085.46 in Q1 2021, which decreased to -¥2,437,809.20 in Q4 2021[30]. - The total operating revenue for 2021 was ¥198,155,466.15, representing a decrease of 26.19% compared to ¥268,479,606.43 in 2020[98]. - The core business of nuclear biochemical safety equipment accounted for 100% of the total operating revenue in 2021, with a gross margin of 49.50%[100]. - The sales volume of nuclear biochemical safety equipment reached 2,235,387 units in 2021, a significant increase of 8,031.64% from 27,490 units in 2020[102]. - The company reported a significant increase in cash management income from trading financial assets, contributing to the overall financial performance[33]. Research and Development - R&D expenses increased to CNY 40.41 million, a year-on-year growth of 43.50%, while marketing expenses rose to CNY 9.78 million, up 125.25%[6]. - The company added 42 new patents and 48 software copyrights during the reporting period, enhancing its intellectual property portfolio[69]. - The company is actively involved in the "14th Five-Year" national key research and development plan, focusing on biosecurity technology and equipment development[70]. - The company has established a comprehensive R&D system, collaborating with various military and academic institutions to ensure technological leadership in nuclear and biochemical safety equipment[62]. - The company has developed over 40 types of nuclear radiation monitoring instruments, widely applied in various fields, demonstrating its strong market presence[94]. - The company is committed to enhancing its market share in the nuclear and biochemical safety sector by improving its product offerings and expanding its sales network for both military and civilian markets[165]. Market Expansion and Strategy - The company aims to enhance its core competitiveness by accelerating the construction of its nuclear biochemical safety equipment industrial base and military-civilian dual-use manufacturing center[10]. - The company plans to expand its market presence through strategic acquisitions and partnerships in the coming years[134]. - The company is actively expanding market channels, focusing on the conversion of military achievements to civilian applications[77]. - The company aims to establish a comprehensive nuclear and biochemical safety industry chain, focusing on both military and civilian applications, and plans to enhance its technological research and development capabilities[161]. - The company anticipates a substantial market release, with potential market space exceeding 100 billion yuan due to government investments in public health and safety initiatives from 2022 to 2024[160]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[200]. - The financial management strategy has yielded a 35.67% reduction in financial expenses, resulting in a net financial income of -¥8,914,512.43[111]. - The company is committed to enhancing operational efficiency and optimizing resource allocation to support growth initiatives[195]. Government and Policy Environment - The company benefits from a favorable policy environment, supported by steady growth in national defense budgets and relevant government policies[48]. - The "14th Five-Year Plan" emphasizes the modernization of national defense and military, aiming for a rational growth in defense spending during this period[40]. - The demand for nuclear and biochemical safety equipment is driven by traditional and non-traditional threats, with a focus on enhancing national security capabilities[41][45]. Talent and Human Resources - The company has implemented a talent strategy focusing on enhancing the quality of its core management and R&D teams, which are crucial for ongoing innovation[95]. - The company’s R&D team consists of 150 members, accounting for 37.69% of total employees, with 39 holding senior titles and 7 possessing doctoral degrees[76]. - The company emphasizes the importance of talent retention and has implemented various incentive measures to maintain a stable core talent team[176]. Risks and Challenges - The company acknowledges risks related to fluctuations in military procurement orders, which could impact revenue if military plans change[174]. - The company recognizes the potential risks associated with the lengthy R&D process for military products, which could affect financial performance if new products do not receive approval[175]. - The company faces risks related to fixed asset depreciation and intangible asset amortization, which may pressure profitability if market conditions worsen[177]. Acquisitions and Investments - The company completed the acquisition of a 51% stake in Beijing Sanan New Special Biological Technology Co., Ltd. for ¥35,000,000.00, with an expected return of ¥2,000,000.00[131]. - The acquisition of a 63% stake in Shanghai Renji Instrument Co., Ltd. was completed with an investment of ¥184,600,000.00, and the expected return is ¥26,818,000.00[134]. - The company has made strategic acquisitions, including Hongjin Jiuan and Shanghai Renji, to enhance its industry structure and core competitiveness[67]. Product Development and Innovation - The company has developed a new generation of decontamination equipment for military applications, with a stable market structure and strong competitive advantages in hydraulic power systems[55]. - A new biological aerosol sampling instrument based on wet wall sampling technology has completed development and is entering mass production, enhancing the performance of similar market products[114]. - The company is advancing a new generation of nuclear biochemical safety detection equipment, which is expected to become a mainstream product in the field[114]. Corporate Governance - The company has established a unified governance and internal control system for its subsidiaries to ensure effective risk management and operational stability[180]. - The company has actively revised and improved its internal control systems to ensure compliance and protect shareholder interests[186]. - The company maintains independence in assets, personnel, finance, organization, and business from its controlling shareholders and actual controllers[187].

Financial Performance - The company's operating revenue for Q1 2022 was ¥14,365,209.21, representing a 132.46% increase compared to ¥6,179,752.62 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥6,964,513.74, a decline of 262.45% from a profit of ¥4,287,085.46 in the previous year[3] - The net cash flow from operating activities was -¥36,173,813.44, a decrease of 127.15% compared to ¥133,261,036.44 in the same period last year[9] - The company's basic earnings per share were -¥0.09, a decrease of 250.00% from ¥0.06 in the same period last year[3] - The weighted average return on equity was -0.51%, down 0.81% from 0.30% in the previous year[3] - The net profit for Q1 2022 was -9,489,779.25 CNY, compared to a net profit of 3,600,874.62 CNY in the same period last year, indicating a significant decline[27] - Operating profit for Q1 2022 was -9,469,402.78 CNY, down from 4,881,748.24 CNY in Q1 2021[27] - The total comprehensive income for Q1 2022 was -9,489,779.25 CNY, compared to 3,600,874.62 CNY in Q1 2021[28] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,588,003,188.55, down 2.87% from ¥1,634,846,444.94 at the end of the previous year[3] - Total liabilities decreased from CNY 229,292,507.52 to CNY 188,509,030.38, a reduction of about 17.8%[24] - The company's equity attributable to shareholders decreased from CNY 1,371,607,022.58 to CNY 1,359,126,763.01, a decline of approximately 0.9%[24] Cash Management - Cash and cash equivalents at the end of the quarter were CNY 538,092,415.28, down from CNY 714,500,324.10 at the beginning of the year, reflecting a decrease of approximately 25%[22] - The company reported a decrease in accounts receivable from CNY 166,111,878.79 at the beginning of the year to CNY 128,778,602.69, a reduction of about 22.5%[22] - Cash and cash equivalents at the end of Q1 2022 stood at 366,550,631.50 CNY, compared to 265,192,082.30 CNY at the end of Q1 2021, showing an increase of approximately 38.2%[32] - The company has utilized idle funds for cash management, including structured deposit products with varying yields, such as a CNY 10,000,000 structured deposit with a yield of 1.3% to 3.60%[20] - The company is actively managing its cash reserves and investments to optimize returns while maintaining liquidity[20] Operational Developments - The company won a military biological inspection vehicle project in March 2022, which is expected to enhance its market share and operational performance[16] - The company has completed the renovation of five industrial plants at the military-civilian manufacturing center project in Mianyang, with a total land area of approximately 68,116.10 square meters[19] - The total auction price for the land use rights and construction in progress for the Mianyang project was 32.85 million RMB[19] - The first phase of the Mianyang project is expected to invest 100 million RMB and has a construction period of 12 months[19] - The portable biological detection box produced by the company's subsidiary was used in the security checks during the 2022 Beijing Winter Olympics[16] Research and Development - Research and development expenses increased by 13.37% to ¥8,258,538.30, attributed to higher personnel costs and increased investment in R&D[8] - Research and development expenses increased to 8,258,538.30 CNY, compared to 7,284,803.05 CNY in the previous year, reflecting a growth of approximately 13.4%[27] - The company is committed to enhancing its core competitiveness through the development of nuclear and biochemical safety equipment[18] - The company has established a strategic layout for a complete industrial chain in nuclear and biochemical safety[18] - The company is actively expanding its market presence and business development in the military and civilian sectors[18] Shareholder Information - The company has a total of 41,872,595 restricted shares, with 575,925 shares released during the reporting period[15] - The company’s major shareholders include Pan Feng with a 25.41% stake and Mao Jianqiang with an 11.97% stake[12] Revenue and Costs - Total operating costs for the first quarter amounted to CNY 27,926,803.47, up from CNY 14,612,372.87, indicating an increase of about 91%[26] - The company reported a total revenue from sales of goods and services of 53,172,884.32 CNY in Q1 2022, down from 181,273,792.66 CNY in the previous year[30]

Financial Performance - The company's revenue for Q3 2021 was ¥83,254,577.41, representing a 25.23% increase compared to the same period last year[3]. - The net profit attributable to shareholders decreased by 4.32% to ¥23,788,259.46, while the year-to-date net profit dropped by 54.35% to ¥33,432,626.77[3]. - The basic earnings per share for Q3 2021 was ¥0.31, down 20.51% from the previous year[3]. - Total revenue for Q3 2021 was CNY 133,475,905.73, a decrease of 26.7% compared to CNY 181,953,152.03 in Q3 2020[33]. - Operating profit for Q3 2021 was CNY 34,345,122.43, down from CNY 83,393,167.99 in the same period last year, reflecting a decline of 58.8%[34]. - Net profit for Q3 2021 was CNY 33,021,964.19, a decrease of 54.7% from CNY 72,921,689.79 in Q3 2020[34]. - The total comprehensive income for the period was CNY 33,021,964.19, compared to CNY 72,921,689.79 in the previous period, indicating a significant decrease[35]. - Basic and diluted earnings per share for the current period were CNY 0.440, down from CNY 1.23 in the previous period[35]. Assets and Liabilities - Total assets increased by 10.45% to ¥1,610,852,161.54 compared to the end of the previous year[3]. - Total assets as of September 30, 2021, amounted to CNY 1,610,852,161.54, an increase from CNY 1,458,508,446.33 at the end of 2020[30]. - Current assets decreased to CNY 1,102,302,096.19 from CNY 1,172,094,501.94, a decline of 6.0%[30]. - Non-current assets increased to CNY 508,550,065.35 from CNY 286,413,944.39, representing a growth of 77.3%[30]. - Total liabilities increased to CNY 204,948,013.23 from CNY 94,613,026.28, reflecting a rise of 117.4%[31]. - Total liabilities amounted to CNY 94,613,026.28, with current liabilities at CNY 89,292,248.82[43]. - Non-current liabilities totaled CNY 5,320,777.46, including lease liabilities of CNY 6,950,599.44[43]. - The company's retained earnings as of September 30, 2021, were CNY 265,265,033.44, compared to CNY 254,931,003.27 at the end of 2020, showing an increase of 4.9%[31]. Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥93,583,624.02, marking a 1,167.57% increase year-to-date[3]. - The net cash flow from operating activities for Q3 2021 was ¥93,583,624.02, an increase of 1167.57% compared to the previous period due to the recovery of accounts receivable[11]. - Net cash flow from investing activities was ¥350,824,963.90, a 162.98% increase attributed to cash management investments using idle funds[11]. - The net cash flow from financing activities decreased to -¥19,794,513.26, a decline of 102.17% compared to the previous period due to an increase in funds received from fundraising[11]. - Cash inflow from operating activities totaled CNY 328,532,114.76, compared to CNY 141,026,817.23 in the previous period, reflecting a strong increase[39]. - Cash outflow from operating activities was CNY 234,948,490.74, up from CNY 149,792,894.24 in the previous period[39]. - The company reported cash and cash equivalents at the end of the period amounting to CNY 678,566,379.92, an increase from CNY 477,142,961.12 in the previous period[39]. - The company received CNY 1,256,653,578.36 from investment recoveries during the current period[39]. - The total cash inflow from financing activities was CNY 3,490,000.00, a significant decrease from CNY 952,143,615.00 in the previous period[39]. - The company paid CNY 22,884,513.26 in dividends and interest during the current period, compared to CNY 794,517.58 in the previous period[39]. Investments and Acquisitions - On August 28, 2021, the company signed an agreement to acquire 63.00% of Shanghai Renji Instrument Co., Ltd., expanding its presence in the nuclear radiation monitoring and protection sector[19]. - The acquisition of Shanghai Renji allows the company to cover a full lifecycle of technology support in nuclear radiation monitoring equipment[19]. - The company aims to optimize its product structure and expand its civilian product business, focusing on nuclear safety industry layout[18]. - The strategic acquisition is a step towards achieving a comprehensive coverage of nuclear safety equipment, enhancing the company's capabilities in detection, protection, and decontamination[19]. - The company signed a project investment agreement with the People's Government of Mianyang City to invest up to RMB 500 million in the construction of a dual-use manufacturing center, with a construction period of 18 months[20]. Corporate Governance - The total number of ordinary shareholders at the end of the reporting period was 14,889[13]. - The largest shareholder, Pan Feng, holds 25.41% of the shares, amounting to 19,515,000 shares[13]. - The company completed the election of the second board of directors and the second supervisory board, enhancing its corporate governance structure[22]. - The company aims to strengthen control over subsidiaries and promote their healthy development through the implementation of a subsidiary management system[22]. Strategic Initiatives - The company completed the registration of its Mianyang branch on July 14, 2021, to enhance market development in the Sichuan-Chongqing region[18]. - The establishment of the dual-use manufacturing center is expected to enhance the company's R&D and production capabilities, contributing to new profit growth points[20]. - The company is focused on expanding its market presence and enhancing core competitiveness through strategic investments and acquisitions[20]. - The company has made progress in cash management using idle raised funds, with various structured deposit products yielding annualized returns ranging from 1.30% to 4.85%[27]. - The company plans to use up to RMB 300 million of its own funds and RMB 550 million of temporarily idle raised funds for cash management, effective for 12 months[24]. Other Information - The company has implemented new leasing standards since January 1, 2021, affecting the recognition of lease liabilities[44]. - The third-quarter report was not audited[45].

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20% compared to RMB 416.67 million in the same period of 2020[16]. - The net profit attributable to shareholders for the first half of 2021 was RMB 50 million, up 25% from RMB 40 million in the first half of 2020[16]. - The company's operating revenue for the reporting period was ¥50,221,328.32, a decrease of 56.51% compared to ¥115,470,046.76 in the same period last year[23]. - The net profit attributable to shareholders was ¥9,644,367.31, down 80.06% from ¥48,368,306.07 year-on-year[23]. - The net cash flow from operating activities increased by 238.98% to ¥109,727,969.08, compared to ¥32,370,077.61 in the previous year[23]. - The basic earnings per share decreased by 84.52% to ¥0.130 from ¥0.84 in the same period last year[23]. - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which was ¥797,080.31, down 98.27% from ¥45,951,270.66[23]. - The total profit for the first half of 2021 was CNY 14,482,576.60, down from CNY 53,891,024.98 in the same period of 2020, marking a decline of 73.1%[181]. - The company reported a fair value change gain of CNY 2,478,401.82 in the first half of 2021, compared to no gain in the same period of 2020[181]. - The company reported a net profit attributable to shareholders of 4.72 million, down from 6.27 million in the same period last year, indicating a decline of approximately 25%[195]. Market Expansion and Strategy - The company plans to expand its market presence by entering two new provinces in China by the end of 2021, aiming for a 15% increase in market share[16]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach[16]. - The company is actively expanding its market presence by participating in military and civilian project tenders, enhancing its product system in the field of nuclear and chemical safety[50]. - The company aims to complete the military cleaning and disinfection equipment production project and the R&D center construction project by the end of the year[53]. - The company is focusing on the development of specialized equipment that combines basic functions to meet the growing demand for nuclear and chemical safety equipment in both military and public safety sectors[45]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its offerings[194]. - The company plans to expand its market presence and invest in new product development to drive future growth[194]. Research and Development - Research and development expenses increased by 30% to RMB 30 million, focusing on new product innovations in hydraulic systems[16]. - The company increased R&D investment to CNY 14.40 million in the first half of the year, a year-on-year growth of 54.00%, accounting for 28.68% of operating revenue[46]. - The company has established a comprehensive research system and has filed for 14 new patents, bringing the total to 90 patents[47]. - The company has a technical R&D team of 130 people, representing 42.20% of total employees, including 28 with senior titles and 8 with doctoral degrees[49]. - The company emphasizes R&D, primarily through military project contracts and independent research, collaborating with various military and academic institutions to ensure technological leadership[33]. - Research and development expenses increased to CNY 14,402,093.63 in the first half of 2021, compared to CNY 9,352,052.36 in the first half of 2020, reflecting a growth of 54.9%[176]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs by the end of 2021[16]. - The company has established a comprehensive procurement management system, selecting qualified suppliers based on specifications and conducting market inquiries[35]. - Production is organized based on orders, with a standardized quality control system in place to ensure timely delivery of products[36][37]. - The company aims to improve its operational efficiency through strategic investments in new technologies[199]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[6]. - The company has established a stable cooperation relationship with military clients, enhancing its market position in the military sector[56]. - The company has maintained a cash management strategy for idle funds, generating interest income of RMB 1,610.54 million[84]. - The company reported a total cash inflow from operating activities of CNY 212,112,179.00, compared to CNY 127,110,696.98 in the previous year, indicating an increase of about 67%[185]. - The total cash outflow for financing activities was CNY 21,687,948.60, which included dividend payments and interest, compared to CNY 12,115,571.86 in the previous year, indicating an increase of about 79%[186]. Risks and Challenges - The company faces risks related to supply chain disruptions, which may impact production schedules and costs[5]. - The company acknowledges the risk of fluctuations in military procurement orders, which could impact revenue due to the long project cycles associated with military contracts[95]. - Seasonal risks are present, as revenue is expected to be concentrated in the second half of the year due to military procurement practices[96]. - The company faces risks related to confidential information disclosure, which may affect investor value judgment due to the nature of its military-related business[94]. - The company is actively expanding its product structure to include public safety and environmental protection markets to mitigate risks from macroeconomic changes[94]. Corporate Governance - There were no changes in the board of directors or senior management during the reporting period, indicating stability in leadership[104]. - The company has no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[124]. - The company did not engage in any significant related party transactions during the reporting period[130]. - The semi-annual financial report was not audited[165]. Environmental and Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties related to environmental issues during the reporting period[109]. - The company completed the environmental protection acceptance for the "Annual Production of 250 Military Vehicle Cleaning and Disinfection Equipment Project" on March 20, 2021, with all pollutants meeting the required standards[110]. - The company has implemented various employee welfare measures, including social insurance and additional benefits, while actively organizing COVID-19 vaccinations for employees[117]. - The company has established environmental protection facilities, ensuring that major pollutants are effectively treated and meet discharge standards[118].

Financial Performance - The company's operating revenue for Q1 2021 was ¥6,179,752.62, representing a 343.96% increase compared to ¥1,391,947.95 in the same period last year[8]. - Net profit attributable to shareholders was ¥4,287,085.46, a significant improvement of 175.93% from a loss of ¥5,646,257.99 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥4,052,985.01, up 169.90% from a loss of ¥5,797,923.13 year-over-year[8]. - Basic earnings per share rose to ¥0.06 from a loss of ¥0.10, marking a 156.95% improvement[8]. - The company reported a total of 18,844 common shareholders at the end of the reporting period[12]. - The company's operating revenue for the first quarter reached ¥6,179,752.62, a year-on-year increase of 343.96% driven by increased product sales[18]. - The net profit attributable to ordinary shareholders was ¥4,287,085.46, reflecting a year-on-year growth of 175.93% primarily from R&D income and sales of training equipment[18]. - The company reported a significant increase in financial income, with financial expenses decreasing by 3203.94% to -¥3,744,147.85 due to effective cash management of idle funds[17]. - The total comprehensive income for Q1 2021 was ¥5,566,393.97, compared to a total comprehensive loss of ¥6,040,531.79 in the previous year[51]. Cash Flow and Assets - The net cash flow from operating activities increased by 93.11% to ¥133,261,036.44, compared to ¥69,007,220.67 in the same quarter last year[8]. - Cash flow from operating activities increased by 93.11% to ¥133,261,036.44, mainly due to the recovery of accounts receivable[17]. - The company's cash and cash equivalents increased to ¥515,192,082.30 from ¥488,412,831.78 at the end of 2020, reflecting a growth of approximately 5.6%[38]. - The accounts receivable decreased significantly to ¥83,204,313.52 from ¥248,808,040.30, indicating a reduction of about 66.6%[38]. - The total assets at the end of the reporting period were ¥1,430,636,082.95, a decrease of 1.91% from ¥1,458,508,446.33 at the end of the previous year[8]. - The total liabilities decreased to ¥58,865,497.16 from ¥94,613,026.28, showing a reduction of approximately 37.9%[40]. - The company's equity attributable to shareholders increased slightly to ¥1,367,938,079.37 from ¥1,363,710,801.61[40]. Research and Development - R&D expenses rose by 59.59% to ¥7,284,803.05, attributed to an increase in R&D personnel and related costs[17]. - Research and development expenses for Q1 2021 amounted to ¥7,284,803.05, up from ¥4,564,562.50 in the previous year, reflecting an increase of approximately 60%[47]. - The company is focusing on R&D in biological sensing and detection technologies to meet military and industrial needs, establishing a stable R&D team[21]. Acquisitions and Investments - The company completed the acquisition of 51% of Beijing Hongjin Jiuan Biotechnology Co., enhancing its capabilities in biological safety monitoring and detection products[19]. - The company completed the acquisition of 51% equity in Beijing Sanan New Special Biotechnology Co., Ltd. (now renamed Beijing Hongjin Jiuan Biotechnology Co., Ltd.)[27]. - The project for military cleaning and disinfection equipment has a total investment of ¥229.25 million, with 65.38% progress achieved[30]. - The new chemical defense equipment and emergency rescue equipment industrialization project has a total investment of ¥249.66 million, with only 8.71% progress[30]. - The research and development center construction project has a total investment of ¥99.60 million, with 50.27% progress achieved[30]. Risks and Future Plans - The company anticipates potential risks from changes in international environments and defense strategies, which could impact production and operations[22]. - The company plans to enhance technical innovation and expand into public safety and environmental protection markets to create new profit growth points[22]. - The company aims to enhance its core competitiveness by optimizing its operational structure and improving its management culture[20]. - 弘进久安 will become a subsidiary, and the company aims to integrate management, culture, and business operations to achieve synergy[21]. Fundraising and Financial Management - The total amount of raised funds is ¥927 million, with ¥39.24 million invested in the current quarter[30]. - Cumulative investment of raised funds reached ¥284.99 million, representing 30.7% of the total raised[30]. - The company has invested idle funds in various financial products, including structured deposits with expected returns ranging from 0.70% to 3.55%[26]. - The company has not encountered any overdue commitments from actual controllers, shareholders, or related parties during the reporting period[28]. - There are no changes in the feasibility of the fundraising projects as of the reporting period[30]. - The company has not reported any unfulfilled commitments from related parties during the reporting period[28]. - The company has not encountered any situations where the fundraising projects did not meet planned progress as of the reporting period[30].

Financial Performance - The company's operating revenue for 2020 was CNY 268,479,606.43, representing a 9.56% increase compared to CNY 245,045,898.09 in 2019[18]. - The net profit attributable to shareholders for 2020 was CNY 100,084,822.71, a 5.21% increase from CNY 95,131,336.92 in 2019[18]. - The total assets at the end of 2020 amounted to CNY 1,458,508,446.33, a significant increase of 224.67% from CNY 449,225,291.48 at the end of 2019[18]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,363,710,801.61, reflecting a 305.12% increase from CNY 336,621,789.26 at the end of 2019[18]. - The company reported a basic earnings per share of CNY 1.56 for 2020, down 5.45% from CNY 1.65 in 2019[18]. - The company achieved total revenue of RMB 268.48 million in 2020, an increase of 9.56% year-on-year[46]. - The net profit attributable to shareholders reached RMB 100.08 million, reflecting a year-on-year growth of 5.21%[46]. - The gross profit margin for the nuclear chemical safety equipment segment was 59.61%, an increase of 2.41% compared to the previous year[60]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2020, representing a year-over-year increase of 15%[121]. Research and Development - The company has established a comprehensive R&D system focusing on nuclear, biological, and chemical safety equipment, continuously enriching its product offerings[27]. - The company has a research and development team of 112 members, accounting for 41.95% of total employees, with 31 senior technical personnel and 6 PhDs[37]. - R&D investment amounted to RMB 28.16 million, accounting for 10.49% of total revenue, representing a 31.00% increase year-on-year[47]. - The company added 26 new patents and 14 software copyrights during the reporting period, enhancing its technological capabilities[48]. - The company aims to enhance its technological R&D capabilities in nuclear, biological, and chemical safety equipment, focusing on military applications[98]. - The establishment of five laboratories will support the company's core technology innovation system, focusing on various aspects of nuclear safety equipment[100]. Market Position and Strategy - The company is a core supplier of hydraulic power systems for the new generation of nuclear, biological, and chemical decontamination vehicles for the military[27]. - The company has established a stable partnership with military clients, ensuring a solid market position in the military sector[40]. - The company is focused on expanding its product offerings and market reach in the nuclear and chemical safety sector, aiming for a comprehensive industry chain[46]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[121]. - The company is actively participating in military bidding projects and expanding its business into civilian markets, leveraging technology and products developed for military applications[106]. Cash Flow and Financial Management - The net cash flow from operating activities was negative CNY 54,876,435.00, a decline of 129.63% compared to CNY 185,203,330.29 in 2019[18]. - The company's net cash flow from operating activities decreased by 52.26% year-on-year, primarily due to accounts receivable from delivered products not being collected[73]. - The net cash flow from investing activities showed a significant outflow of 732,367,675.41 yuan, an increase of 551.89% compared to the previous year, mainly due to increased investments in fixed assets and cash management of temporarily idle raised funds[73]. - The net cash flow from financing activities increased by 3,141.31% year-on-year, amounting to 895,535,289.84 yuan, primarily due to funds raised from the initial public offering[73]. Profit Distribution - The company reported a profit distribution plan of 3 RMB per 10 shares (including tax) based on 76,795,963 shares[5]. - The total distributable profit for the year was RMB 90,281,670.96, with a cash dividend of RMB 23,038,788.90 proposed, equating to RMB 3.00 per 10 shares[116][117]. - The cash dividend represents 23.02% of the net profit attributable to shareholders for 2020[119]. - The company has a capital reserve of RMB 1,004,882,714.78 as of the end of 2020[116]. - The company plans to carry forward the remaining undistributed profits to the next fiscal year[117]. Governance and Compliance - The company has established a comprehensive governance structure to ensure fair and transparent shareholder rights, adhering to relevant laws and regulations[168]. - The company has committed to compensating investors for any losses incurred due to unfulfilled commitments, with specific measures outlined for accountability[134]. - The company will publicly disclose reasons for any unfulfilled commitments and work to minimize investor losses[135]. - The company has confirmed that all commitments to minority shareholders have been fulfilled on time[135]. - The company will enhance its governance structure and talent acquisition efforts to improve overall operational efficiency[101]. Risks and Challenges - The company faces risks related to the disclosure of sensitive information, which may affect investors' valuation judgments due to the inability to disclose certain classified information[103]. - The company has a high customer concentration, with sales to the top five customers accounting for over 95% of total revenue from 2018 to 2020, which poses a risk to revenue stability[106]. - The company is at risk of losing key technical personnel due to competition, which could adversely affect its business operations and R&D efforts[108]. - The company's main products are subject to military procurement plans, which can be unpredictable and may lead to revenue uncertainty if procurement schedules change[107]. Initial Public Offering (IPO) - The company successfully completed its IPO in August 2020, raising RMB 1,019.47 million, which strengthened its financial position[49]. - The company completed its initial public offering (IPO) of 19,199,000 shares at a price of 53.10 RMB per share, increasing total shares from 57,596,963 to 76,795,963[182]. - The proportion of limited sale shares decreased from 100% to 75% after the IPO, while unrestricted shares accounted for 25% of the total[182]. - The company raised a total of RMB 1,019.47 million through the issuance of 19,199,000 shares at a price of RMB 53.10 per share[189]. Social Responsibility - The company actively participated in social responsibility initiatives during the pandemic, donating 65,540 CNY worth of medical supplies, including 200 KN95 masks and 260 protective suits[172]. - The company developed a nuclear and chemical biological isolation transfer cabin in response to the pandemic, donating the first batch to hospitals and medical centers[173].

Financial Performance - Operating revenue for the period was ¥66,483,105.27, a decrease of 4.53% compared to the same period last year[8] - Net profit attributable to shareholders was ¥24,862,099.07, down 8.10% year-over-year[8] - Basic earnings per share decreased by 17.02% to ¥0.39[8] - Weighted average return on equity was 6.26%, down 1.47% from the previous year[8] - Total operating revenue for Q3 2020 was CNY 66,483,105.27, a decrease from CNY 69,637,446.31 in the previous period[41] - Net profit for Q3 2020 was CNY 24,751,524.02, down from CNY 26,930,195.91 in the same period last year[43] - Total operating revenue for the current period reached ¥181,953,152.03, an increase from ¥165,142,196.22 in the previous period, representing a growth of approximately 10.99%[50] - Net profit for the current period was ¥72,921,689.79, compared to ¥60,430,013.29 in the previous period, indicating a year-over-year increase of about 20.73%[51] - The total comprehensive income for the current period was ¥25,869,513.84, down from ¥27,377,099.59 in the previous period, indicating a decrease of approximately 5.51%[48] Assets and Liabilities - Total assets reached ¥1,432,017,588.67, an increase of 218.77% compared to the previous year[8] - The company's total liabilities decreased to CNY 94,767,526.75 from CNY 111,901,108.99, showing a reduction of approximately 15%[35] - The company's total liabilities amounted to 105,710,580.69 CNY, reflecting a stable financial position despite operational challenges[67] - Total liabilities amounted to CNY 111,901,108.99, with total equity at CNY 337,324,182.49, resulting in total assets of CNY 449,225,291.48[68] - The company’s total current liabilities included short-term loans of CNY 11,138,697.09 and accounts payable of CNY 14,545,144.88[71] Shareholder Information - The company reported a total of 24,351 common shareholders at the end of the reporting period[12] - The top shareholder, Pan Feng, holds 25.41% of the shares, totaling 19,515,000 shares[12] - The equity attributable to owners increased significantly to CNY 1,004,882,714.78 from CNY 97,077,525.14, marking an increase of over 935%[35] - The company's equity attributable to shareholders rose to CNY 1,326,880,913.11 from CNY 326,108,184.58[39] Cash Flow - Net cash flow from operating activities was -¥41,136,154.62, a decline of 451.75% compared to the previous year[8] - The company reported a net cash outflow from operating activities of ¥8,766,077.01, a significant decline compared to a net inflow of ¥95,265,514.56 in the previous period[59] - Cash inflow from financing activities amounted to 952,143,615.00 CNY, leading to a net cash flow from financing activities of 914,288,789.06 CNY after accounting for outflows[63] - The company’s cash inflow from operating activities totaled ¥141,026,817.23, down from ¥224,565,924.41 in the previous period, indicating a decrease of about 37%[59] Investments and Expenditures - The company invested 500,000,000.00 CNY in fixed assets, a significant increase from 4,000,000.00 CNY in the previous period, highlighting a focus on capital expenditure[60] - The company utilized ¥50,000.00 million of idle raised funds for structured deposit products[22] Research and Development - Research and development expenses for Q3 2020 were CNY 7,293,053.64, compared to CNY 6,679,647.57 in the previous year[42] - Research and development expenses amounted to ¥16,645,106.00, compared to ¥15,336,159.06 in the previous period, showing an increase of approximately 8.55%[50] Compliance and Governance - The company has not reported any non-compliance with external guarantees during the reporting period[26] - There were no overdue commitments from major shareholders or related parties during the reporting period[27] - The company has not conducted an audit for the third quarter report[74]